# Track what changes after PRP care *Best PRP Therapy Arizona | Understand Changes in Soreness* > Learn why soreness can change after care and how to judge whether the change matters in your daily life. Start with one daily task that soreness has made harder. It might be getting up, reaching a shelf, or walking outside. Track that task before and after any care. Feeling better matters, but the reason isn't always clear. Rest, time, hope, exercise, and other care can all change soreness. A fair test tries to sort those effects apart. ## Notice changes you can use in daily life Choose a task you do most days. Write down how far, high, or long you can do it. Simple notes are enough for this job. Use the same task each time so the change is easier to see. Switching tasks is like changing rulers halfway through a job. You may miss a small gain or mistake a good day for lasting help. Ask when a change may start and how long to watch. Find out which signs mean the plan isn't working. Don't wait without knowing when the next check will happen. A change that helps daily life can matter even when soreness remains. You and your provider can decide whether that gain justifies the cost, travel, and recovery. The choice doesn't belong to a review page. ## Ask what else could explain the change Your soreness may ease because you rested or changed a hard motion. Exercise, sleep, and simple support can also help. That doesn't make the change less real. The catch is knowing what caused it. Ask whether other care continued at the same time. Then ask how often people with your kind of problem get useful relief. Concentrated PRP is one regenerative choice at QC Kinetix. Its medical providers can explain the purpose of that care and where doubt remains. They can't know your result before they examine you. Bring your task notes to each follow-up. Tell the provider what changed and what didn't. Plain facts from your own week are often easier to use than a broad claim. ## Evidence sources 1. A meta-analysis of 73 articles covering 5,895 patients quantified the PLACEBO response to intra-articular injection in knee osteoarthritis: statistically and clinically significant improvements in pain, function and quality of life at 1, 3 and 6 months, with responder rates above 50% at each of those points, declining by 12 months. The placebo response was stronger in trials with more female participants and in more recently published trials. This is why an uncontrolled 'our patients improved' figure carries almost no information. Previtali D, Boffa A, Di Laura Frattura G, et al. — [Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression](https://pubmed.ncbi.nlm.nih.gov/41031623/). *EFORT Open Reviews*, 2025. 2. A Bayesian network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 trials, 22,795 participants, 18 intra-articular interventions) found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, the effects of 16 of the 18 intra-articular interventions in knee or hip OA were smaller than the minimal clinically important difference and most were consistent with placebo effects; triamcinolone had the highest probability of exceeding the MID at weeks 2-6. Pereira TV, Saadat P, Bobos P, et al. — [Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/39265924/). *Osteoarthritis and Cartilage*, 2025. 3. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA. Bennell KL, Paterson KL, Metcalf BR, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. 4. A 24-site, 240-patient participant-blinded randomized trial of a single intratendinous PRP injection versus a sham (subcutaneous dry needle) for chronic midportion Achilles tendinopathy found VISA-A scores of 54.4 versus 53.4 at six months (adjusted mean difference -2.7; 95% CI -8.8 to 3.3) against a 12-point minimal clinically important difference. The authors stated the findings do not support the use of this treatment for chronic midportion Achilles tendinopathy. Kearney RS, Ji C, Warwick J, et al. — [Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy: A Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/34255009/). *JAMA*, 2021. 5. PATH-2 randomised 230 adults with acute Achilles tendon rupture managed non-surgically to PRP or a placebo dry-needle injection across 19 UK hospitals, with a central laboratory confirming the PRP was of good quality with the expected growth-factor content. At 24 weeks there was no detectable difference in muscle-tendon function (limb symmetry index 34.7% versus 38.5%; adjusted mean difference -3.9%; 95% CI -10.5% to 2.7%) or in any secondary outcome or adverse-event rate. Keene DJ, Alsousou J, Harrison P, et al. — [Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial](https://pubmed.ncbi.nlm.nih.gov/31748208/). *BMJ*, 2019. 6. A meta-analysis of 34 randomized trials (1403 PRP knees, 1426 control knees) found WOMAC favoured PRP over placebo at 12 months (P=.02) and over hyaluronic acid at 6 and 12 months (P<.001), and favoured PRP over steroids on VAS pain and KOOS at 6 months. Critically, the authors reported that the superiority of PRP did NOT reach the minimal clinically important difference for any outcome, and graded the quality of evidence as low. Filardo G, Previtali D, Napoli F, et al. — [PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/32551947/). *Cartilage*, 2021. 7. A network meta-analysis of 11 randomized trials (1353 patients) with HIP osteoarthritis found that for both pain and function, at 2-4 months and at 6 months, NO intervention - corticosteroid, hyaluronic acid or PRP - significantly outperformed an intra-articular saline placebo injection. Gazendam A, Ekhtiari S, Bozzo A, et al. — [Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials](https://pubmed.ncbi.nlm.nih.gov/32829298/). *British Journal of Sports Medicine*, 2021. 8. A Delphi consensus of 24 invited experts produced the Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO) checklists: 58 items reached consensus for PRP and were compiled into a 23-statement reporting checklist, with a parallel 25-statement checklist for mesenchymal stem cells. The need for it was identified because clinical studies of PRP and MSCs are 'limited by inadequate reporting of scientific details critical to outcome'. Murray IR, Geeslin AG, Goudie EB, et al. — [Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells](https://pubmed.ncbi.nlm.nih.gov/28509821/). *Journal of Bone and Joint Surgery (American)*, 2017. 9. A placebo-controlled, double-blind randomized trial of 40 patients with chronic rotator cuff tendinopathy compared a single ultrasound-guided subacromial injection of 5 mL PRP with 5 mL saline, with both groups completing a 6-week standard exercise programme and follow-up to one year. PRP did not produce better outcomes than saline on any measure - a reminder that the exercise programme, not the injectate, carried the improvement. Kesikburun S, Tan AK, Yilmaz B, et al. — [Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up](https://pubmed.ncbi.nlm.nih.gov/23893418/). *American Journal of Sports Medicine*, 2013. ## Know where this link goes The link below reaches QC Kinetix and sits apart from the clinic reviews. It doesn't promise that any care will fit you. book a free consultation: --- Clear help for a sore joint and your next visit. This Arizona PRP clinic guide helps you understand joint soreness, compare offices, and prepare for a useful visit. Plain help for understanding joint soreness and preparing for an Arizona clinic visit. The owners of the Phoenix-area QC Kinetix clinics operate this publication, QC Kinetix may appear in its roundups, and those owners have a commercial interest in bookings made through the consultation link. Clinic names, public-source facts, dates, and placement come from the signed review dataset and renderer; treatment evidence comes from the signed PRP corpus. © 2026 Arizona PRP Field Notes. Educational information is not medical advice.